Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Pharmaceutical manufacturing giant Eli Lilly and Co. is exploring potential economic incentives for a $5.9B biomanufacturing ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly and Company discovers, develops ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Mounjaro. Ozempic. Wegovy. Zepbound. All these are brand names linked in some way to diabetes and weight loss-or, as the ...

Eli Lilly, the manufacturer of Mounjaro (tirzepatide), offers a savings card program for eligible participants. Other resources may also be available to help you save on the cost of your Mounjaro ...